Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III

Conditions

Ischemic Stroke, Acute

Keywords

tenecteplase, alteplase, ischemic stroke, phase 3 trial

Brief summary

The trial is a phase 3, multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled design. Patients with acute ischemic stroke due to anterior circulation large vessel occlusion within 4.5-24 hours from last known well (including wake-up stroke and unwitnessed stroke) will be randomized 1:1 to 0.25mg/kg intravenous tenecteplase or standard medical treatment.

Detailed description

The study will be a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE), controlled phase 3 trial (2 arms with 1:1 randomization) in ischemic stroke due to anterior circulation large vessel occlusion with perfusion mismatch up to 24 hours of symptom onset. The target mismatch profiles on CTP or MRI perfusion weighted imaging include ischemic core volume \<70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL demonstrated by a certified automatic software. The minimum sample size is 516 patients.

Wang H, Cao Z, Campbell BCV, Katsanos AH, Yin J, Fisher M, Wang Y, Xiong Y.

2026-05-20

10.1007/s40120-026-00958-4

Clinical benefit of tenecteplase despite failed recanalization in late-window ischemic stroke: a post hoc analysis of the TRACE-3 trial

Zhengzhao Lu, Z Wang, Aoming Jin, F Y, Lihua Wang et al. (14 authors)

BMC Medicine2026-04-16

10.1186/s12916-026-04877-x

Infarct Growth Rate and Tenecteplase Benefit in Ischemic Stroke at 4.5 to 24 Hours Without Thrombectomy --A Secondary Analysis of the TRACE-Ⅲ Randomized Trial.

Wang L, Zhou L, Yin J, Jin A, Campbell B, Fisher M, Schwamm L, Parsons M, Meng X, Duan C, Zong L, Ye W, Che F, Wang LH, Dai H, Wang H, Wang Z, Hao M, Cao Z, Wu S, Wang Y, Xiong Y.

2026-04-07

10.1177/17474930261443408

Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial.

Cheng X, Hong L, Churilov L, Lin L, Ling Y, Zhang J, Yang J, Geng Y, Wu D, Liu X, Zhou X, Zhao Y, Zhai Q, Zhao L, Chen Y, Guo Y, Yu X, Gong F, Sui Y, Li G, Yang L, Gu HQ, Wang Y, Parsons M, Dong Q, CHABLIS-T collaborators.

2024-11-0513 citations

10.1136/svn-2023-002820

Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy

Yunyun Xiong, Bruce Campbell, Lee H. Schwamm, Meng Xia, Aoming Jin et al. (30 authors)

New England Journal of Medicine2024-06-15145 citations

10.1056/nejmoa2402980

Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial

Yunyun Xiong, Bruce Campbell, Marc Fisher, Lee H. Schwamm, Mark Parsons et al. (10 authors)

Stroke and Vascular Neurology2023-05-2914 citations

10.1136/svn-2023-002310

Interventions

DRUGtenecteplase (0.25 mg/kg, Max 25 mg)

tenecteplase (0.25 mg/kg) is being used.

DRUGstandard medical treatment

Aspirin combined with clopidogrel, aspirin alone, or clopidogrel alone are being used.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

1. Age ≥18 years old; 2. Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment; including wake-up stroke and unwitnessed stroke, onset time refers to last-seen normal time; 3. Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CTA/MRA, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke; 4. Pre-stroke modified Rankin scale (mRS) score≤1; 5. Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive); 6. Neuroimaging: target mismatch profile on CTP or MRI+MR Perfusion (ischemic core volume \<70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL; 7. Written informed consent from patients or their legally authorized representatives.

Exclusion criteria

1. Intended to proceed to endovascular treatment; 2. Allergy to tenecteplase; 3. Rapidly improving symptoms at the discretion of the investigator; 4. NIHSS consciousness score 1a \>2, or epileptic seizure, hemiplegia after seizures ( Todd's palsy ) or other neurological/mental illness such that the patient is not able to cooperate or unwilling to cooperate; 5. Persistent blood pressure elevation (systolic ≥180 mmHg or diastolic ≥100 mmHg), despite blood pressure-lowering treatment; 6. Blood glucose \<2.8 or \>22.2 mmol/L (point of care glucose testing is acceptable ); 7. Active internal bleeding or at high risk of bleeding, e.g., major surgery, trauma or gastrointestinal or urinary tract hemorrhage within the previous 21 days, or arterial puncture at a non-compressible site within the previous 7 days; 8. Any known impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, then INR \>1.7 or prothrombin time \>15 seconds; use of any direct thrombin inhibitors or direct factor Xa inhibitors during the last 48 hours unless reversal of effect can be achieved with a reversal agent; any full dose heparin/heparinoid during the last 24 hours or with an elevated aPTT greater than the upper limit of normal; 9. Known defect of platelet function or platelet count below 100,000/mm3 (NB patients taking antiplatelet medication can be included); 10. Ischemic stroke or myocardial infarction in previous 3 months, previous intracranial hemorrhage, severe traumatic brain injury or intracranial or intraspinal operation in previous 3 months, or known intracranial neoplasm, arteriovenous malformation or giant aneurysm; 11. Any terminal illness such that the patient would not be expected to survive more than 1 year; 12. Unable to perform CTP or PWI; 13. Hypodensity in \>1/3 MCA territory on non-contrast CT; 14. Acute or past intracerebral hemorrhage (ICH) identified by CT or MRI; 15. Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion); 16. Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial; 17. Unlikely to adhere to the trial protocol or follow-up; 18. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study; 19. Participation in other interventional clinical trials within the previous 3 months.

Design outcomes

Primary

Measure	Time frame	Description
Excellent functional outcome	90 days	Proportion of excellent functional outcome defined as an mRS score ≤ 1 at 90 days

Secondary

Measure	Time frame	Description
Favorable functional outcome	90 days	Proportion of favorable functional outcome defined by an mRS score ≤ 2 point at 90 days
Clinical response rate at 72 hours	72 hours	Clinical response rate at 72 hours defined by an improvement on NIHSS score ≥8 points compared with the initial deficit or a score ≤1.
The rate of improvement on reperfusion	24 hours	The rate of improvement on reperfusion at 24 hours (improved by 90% on Tmax\>6s)
NIHSS change from baseline	7 days	NIHSS change from baseline at 7 days
Ordinal distribution of mRS	90 days	Ordinal distribution of mRS at 90 days.
Mortality	90 days	Rate of death from any cause within 90 days
Systemic bleeding	90 days	Rate of systemic bleeding at 90 days (as defined by The Global Utilisation of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries \[GUSTO\]: moderate and severe bleeding)
Adverse events ( AEs ) / serious adverse events ( SAEs )	90 days	Rate of adverse events ( AEs ) / serious adverse events ( SAEs ) within 90 days
Symptomatic intracranial hemorrhage	36 hours	Proportion of symptomatic intracranial hemorrhage (sICH) within 36 hours (as defined by The European Cooperative Acute Stroke Study III criteria \[ECASSIII\])

Countries

China

Outcome results

None listed